Table 5. Response to anti-PD-1 treatment of NSCLC with/without irTD.
| Variables | All patients (n=132) | TTF-1-positive NSCLC (n=67) | TTF-1-negative NSCLC (n=65) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| With irTD (n=19) | Without irTD (n=113) | P value | With irTD (n=6) | Without irTD (n=61) | P value | With irTD (n=13) | Without irTD (n=52) | P value | |||
| Response, No. [%] | |||||||||||
| Complete response | 0 | 2 [2] | 0 | 2 [3] | 0 | 0 | |||||
| Partial response | 9 [47] | 31 [27] | 3 [50] | 15 [25] | 6 [46] | 16 [31] | |||||
| Stable disease | 6 [32] | 11 [10] | 1 [17] | 2 [3] | 5 [38] | 9 [17] | |||||
| Progressive disease | 4 [21] | 69 [61] | 2 [33] | 42 [69] | 2 [15] | 27 [52] | |||||
| Objective response rate | 47% | 29% | 0.181 | 50% | 28% | 0.353 | 46% | 31% | 0.336 | ||
| Disease control rate | 79% | 39% | 0.002 | 67% | 31% | 0.171 | 85% | 48% | 0.027 | ||
anti-PD-1, anti-programmed cell death protein-1; NSCLC, non-small cell lung cancer; irTD, immune-related thyroid dysfunction; TTF-1, thyroid transcription factor-1.